Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Other financing activities (2021 - 2023)

Cullinan Therapeutics has reported Other financing activities over the past 3 years, most recently at $7.5 million for Q4 2023.

  • Quarterly results put Other financing activities at $7.5 million for Q4 2023, down 71.95% from a year ago — trailing twelve months through Dec 2023 was $30.4 million (down 35.58% YoY), and the annual figure for FY2025 was $36.0 million, down 4.72%.
  • Other financing activities for Q4 2023 was $7.5 million at Cullinan Therapeutics, down from $7.7 million in the prior quarter.
  • Over the last five years, Other financing activities for CGEM hit a ceiling of $26.8 million in Q4 2022 and a floor of $3.5 million in Q1 2021.
  • Median Other financing activities over the past 3 years was $7.4 million (2023), compared with a mean of $9.4 million.
  • Biggest five-year swings in Other financing activities: surged 106.67% in 2022 and later plummeted 71.95% in 2023.
  • Cullinan Therapeutics' Other financing activities stood at $23.5 million in 2021, then rose by 14.29% to $26.8 million in 2022, then plummeted by 71.95% to $7.5 million in 2023.
  • The last three reported values for Other financing activities were $7.5 million (Q4 2023), $7.7 million (Q3 2023), and $7.9 million (Q2 2023) per Business Quant data.